One Piece finally closed out the interlude from Egghead Island with episode #1122, and here's everything about when episode ...

WAYNE, Pa. and ROCKVILLE, Md. - Avalo Therapeutics, Inc. (NASDAQ: AVTX), a biotech firm focusing on immune dysregulation treatments with a market capitalization of $91 million, today announced the ...

WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation ...

Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) – Wedbush raised their Q2 2025 earnings per share estimates for shares of Avalo Therapeutics in a research note issued to investors on ...

Avalo Therapeutics stock opened at $7.66 on Thursday. The business’s fifty day simple moving average is $7.45 and its two-hundred day simple moving average is $9.12. Avalo Therapeutics has a 12 ...

and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced ...

WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation ...

As of March 20, 2025, the average one-year price target for Avalo Therapeutics is $33.66/share. The forecasts range from a low of $18.18 to a high of $50.40. The average price target represents an ...